The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model

Introduction: The objective of this study was to assess the incremental costs and benefits of the 9-valent HPV vaccine (9vHPV) compared with the quadrivalent HPV vaccine (4vHPV). Like 4vHPV, 9vHPV protects against HPV types 6, 11, 16, and 18. 9vHPV also protects against 5 additional HPV types 31, 33...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Hum Vaccin Immunother
Päätekijät: Chesson, Harrell W., Markowitz, Lauri E., Hariri, Susan, Ekwueme, Donatus U., Saraiya, Mona
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4964746/
https://ncbi.nlm.nih.gov/pubmed/26890978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1140288
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia